CONTACT

+91 80 2808 2808

info@biocon.com

Press Releases 2018

Biocon / News – Posts / Press Releases / Press Releases 2018

Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children’s Park to the Community

Sun, 02-Dec-2018
Posted by: BIOCON

Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018

Tue, 30-Oct-2018
Posted by: BIOCON

Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%

Thu, 25-Oct-2018
Posted by: BIOCON

Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab

Fri, 19-Oct-2018
Posted by: BIOCON

Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

Fri, 21-Sep-2018
Posted by: BIOCON

Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr

Thu, 26-Jul-2018
Posted by: BIOCON

Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA

Thu, 28-Jun-2018
Posted by: BIOCON

U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®

Tue, 05-Jun-2018
Posted by: BIOCON

Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018

Mon, 04-Jun-2018
Posted by: BIOCON

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA

Sat, 02-Jun-2018
Posted by: BIOCON

1
2